Julia Mueller, an MRC-funded PhD student at the University of Manchester, reflects on how a three-month Policy Internship with the MRC has changed her appreciation of Researchfish and the work done by research funding bodies.
Before I began my three-month internship at the MRC, my idea of the role of research funders was pretty simple. They have the money. We (the researchers) must get the money from them. The end. Actually working in the head office of one of the main funding bodies of medical research gave me a slightly more nuanced insight.
Last year a UK-China research collaboration took an unexpected turn following the discovery of resistance to the ‘last resort’ antibiotic: colistin. Here Professor Timothy Walsh, Professor of Medical Microbiology at Cardiff University, describes how the global community can learn from the positive steps taken by the Chinese Government.
Antibiotic resistance is really all about people and society. We often blame antimicrobial resistance on the bug and how resistance can travel from one bug to another. But different sectors, for example farming, hospitals and communities, are all critically linked.
Today the MRC and a group of partner organisations issued an update on what we have been doing to address of reproducibility and reliability of research since the publication of the report of our symposium on the issue last year. Dr Frances Rawle, our Head of Corporate Governance and Policy, talks about what we’ve done so far.
Reproducibility is everyone’s problem. If we can’t ensure that our results are reliable, then our research can’t improve human health.
Everyone involved in biomedical research, including funders, individual researchers, research institutes, universities, publishers and academies – must play a part in improving research practices.
We’ve worked across the sector to discover the main causes of irreproducible results and what we can do to improve the situation. Read more